Next Article in Journal
The Oligomycin-Sensitivity Conferring Protein of Mitochondrial ATP Synthase: Emerging New Roles in Mitochondrial Pathophysiology
Next Article in Special Issue
Importance of Kupffer Cells in the Development of Acute Liver Injuries in Mice
Previous Article in Journal
The Relationship between Dioxin Congeners in the Breast Milk of Vietnamese Women and Sister Chromatid Exchange
Previous Article in Special Issue
Molecular Mechanisms and New Treatment Strategies for Non-Alcoholic Steatohepatitis (NASH)
Article Menu

Export Article

Open AccessReview
Int. J. Mol. Sci. 2014, 15(5), 7500-7512;

Current Status in the Therapy of Liver Diseases

Department of Nuclear Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany
Ruprecht-Karls-University, Institute of Pharmacy and Molecular Biotechnology, Im Neuenheimer Feld 329, 69120 Heidelberg, Germany
Author to whom correspondence should be addressed.
Received: 24 February 2014 / Revised: 26 March 2014 / Accepted: 3 April 2014 / Published: 30 April 2014
(This article belongs to the Collection Molecular Mechanisms of Human Liver Diseases)
Full-Text   |   PDF [922 KB, uploaded 19 June 2014]


Hepatic diseases, like viral hepatitis, autoimmune hepatitis, hereditary hemochromatosis, non-alcoholic fatty liver disease (NAFLD) and Wilson’s disease, play an important role in the development of liver cirrhosis and, hence, hepatocellular carcinoma. In this review, the current treatment options and the molecular mechanisms of action of the drugs are summarized. Unfortunately, the treatment options for most of these hepatic diseases are limited. Since hepatitis B (HBV) and C (HCV) infections are the most common causes of liver cirrhosis and hepatocellular carcinoma, they are the focus of the development of new drugs. The current treatment of choice for HBV/HCV infection is an interferon-based combination therapy with oral antiviral drugs, like nucleos(t)ide analogues, which is associated with improving the therapeutic success and also preventing the development of resistances. Currently, two new protease inhibitors for HCV treatment are expected (deleobuvir, faldaprevir) and together with the promising drug, daclatasvir (NS5A-inhibitor, currently in clinical trials), adequate therapy is to be expected in due course (circumventing the requirement of interferon with its side-effects), while in contrast, efficient HBV therapeutics are still lacking. In this respect, entry inhibitors, like Myrcludex B, the lead substance of the first entry inhibitor for HBV/HDV (hepatitis D) infection, provide immense potential. The pharmacokinetics and the mechanism of action of Myrcludex B are described in detail. View Full-Text
Keywords: hepatic diseases; hepatitis; entry inhibitors; molecular mechanisms; liver cirrhosis; hepatocellular carcinoma hepatic diseases; hepatitis; entry inhibitors; molecular mechanisms; liver cirrhosis; hepatocellular carcinoma
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Uhl, P.; Fricker, G.; Haberkorn, U.; Mier, W. Current Status in the Therapy of Liver Diseases. Int. J. Mol. Sci. 2014, 15, 7500-7512.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top